Why the study?
Does morphine co-administered with P2Y12 receptor antagonists impair platelet inhibition and affect patient outcomes in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes
Design
Review
Authors
Loading...
No increased ischemic events with morphine in ACS on DAPT; leaves open need for randomized trials.
Does morphine co-administered with P2Y12 receptor antagonists impair platelet inhibition and affect patient outcomes in patients with acute coronary syndromes?
This review examines the evidence regarding the potential interaction between morphine and P2Y12 receptor antagonists in ACS patients, which may lead to impaired platelet inhibition.
Γιαννόπουλος et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: